Rachel Vatnsdal

Stock Analyst at JP Morgan

(4.47)
# 324
Out of 5,033 analysts
65
Total ratings
63.04%
Success rate
18.48%
Average return

Stocks Rated by Rachel Vatnsdal

Henry Schein
Aug 7, 2025
Maintains: Overweight
Price Target: $80$76
Current: $63.70
Upside: +19.31%
Adaptive Biotechnologies
Aug 6, 2025
Maintains: Overweight
Price Target: $10$14
Current: $17.75
Upside: -21.10%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $17$14
Current: $15.13
Upside: -7.47%
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $32.16
Upside: -3.61%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12$9
Current: $13.05
Upside: -31.03%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40$33
Current: $32.21
Upside: +2.45%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200$190
Current: $157.67
Upside: +20.50%
Revvity
Apr 29, 2025
Maintains: Neutral
Price Target: $120$100
Current: $95.20
Upside: +5.05%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20$19
Current: $20.09
Upside: -5.43%
Waters
Mar 6, 2025
Maintains: Neutral
Price Target: $380$390
Current: $344.37
Upside: +13.25%
Downgrades: Neutral
Price Target: $50$55
Current: $94.04
Upside: -41.51%
Maintains: Overweight
Price Target: $50$55
Current: $69.80
Upside: -21.20%
Maintains: Overweight
Price Target: $165$160
Current: $144.13
Upside: +11.01%
Maintains: Overweight
Price Target: $650$670
Current: $544.07
Upside: +23.15%
Maintains: Underweight
Price Target: $17$20
Current: $7.96
Upside: +151.26%
Maintains: Neutral
Price Target: $1,300$1,400
Current: $1,358.70
Upside: +3.04%
Downgrades: Neutral
Price Target: n/a
Current: $1.98
Upside: -
Upgrades: Overweight
Price Target: $60$90
Current: $38.14
Upside: +135.97%
Maintains: Overweight
Price Target: $250$270
Current: $209.76
Upside: +28.72%